Provided by Tiger Trade Technology Pte. Ltd.

Esperion Therapeutics

2.74
-0.1100-3.86%
Post-market: 2.740.0014+0.05%16:45 EDT
Volume:2.32M
Turnover:6.44M
Market Cap:703.66M
PE:-25.11
High:2.84
Open:2.82
Low:2.73
Close:2.85
52wk High:4.18
52wk Low:0.6925
Shares:256.81M
Float Shares:237.00M
Volume Ratio:0.51
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1091
EPS(LYR):-0.1091
ROE:97.76%
ROA:9.30%
PB:-2.33
PE(LYR):-25.11

Loading ...

Esperion Therapeutics: Agreement Resolves Patent Litigation Brought by Esperion in Response to Alkem's Andas for Generic Nexletol, Nexlizet

THOMSON REUTERS
·
Feb 17

Esperion Therapeutics Inc - Alkem Agrees Not to Market Generic Nexletol or Nexlizet in US Before April 19, 2040

THOMSON REUTERS
·
Feb 17

Esperion Reaches Settlement Agreement With Fifth Anda Filer Not to Market Generic Version of Nexletol® (Bempedoic Acid) & Nexlizet® (Bempedoic Acid & Ezetimibe) Prior to April 19, 2040

THOMSON REUTERS
·
Feb 17

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

GlobeNewswire
·
Feb 17

Esperion Therapeutics Grants 40,200 Inducement RSUs to New Employees

Reuters
·
Feb 12

Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Feb 12

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 12

Esperion (ESPR) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Jan 28

Piper Sandler Sticks to Their Buy Rating for Esperion (ESPR)

TIPRANKS
·
Jan 16

Esperion reports preliminary FY25 revenue $400M-$408M, consensus $393.11M

TIPRANKS
·
Jan 12

BRIEF-Esperion Reports $156 To $160 Million In Preliminary Full-Year 2025 U.S. Net Product Sales

Reuters
·
Jan 12

Esperion Therapeutics Projects 2025 Revenue Up to $408 Million and Operating Expenses Up to $245 Million for 2026

Reuters
·
Jan 12

Esperion Therapeutics Inc - Reports $156 to $160 Mln in Preliminary* Full-Year 2025 U.S. Net Product Sales

THOMSON REUTERS
·
Jan 12

Esperion Provides Business Update at 44TH Annual J.p. Morgan Healthcare Conference

THOMSON REUTERS
·
Jan 12

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
Jan 12

BRIEF-Esperion Announces Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Dec 10, 2025

Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 10, 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 10, 2025

Esperion Therapeutics Shares Rise After Piper Sandler Initiates Coverage

MT Newswires Live
·
Nov 26, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW,  Kohl's

Reuters
·
Nov 25, 2025